Serina Therapeutics Inc - Asset Resilience Ratio
Serina Therapeutics Inc (SER) has an Asset Resilience Ratio of 83.31% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Serina Therapeutics Inc (SER) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Serina Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Serina Therapeutics Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Serina Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Serina Therapeutics Inc (SER) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $8.62 Million | 69.44% |
| Short-term Investments | $1.72 Million | 13.86% |
| Total Liquid Assets | $10.34 Million | 83.31% |
Asset Resilience Insights
- Very High Liquidity: Serina Therapeutics Inc maintains exceptional liquid asset reserves at 83.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Serina Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Serina Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 72.23% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Serina Therapeutics Inc (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Serina Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 54.61% | $3.67 Million | $6.72 Million | +50.76pp |
| 2023-12-31 | 3.85% | $345.00K | $8.97 Million | -16.05pp |
| 2022-12-31 | 19.90% | $645.00K | $3.24 Million | -11.69pp |
| 2021-12-31 | 31.59% | $996.45K | $3.15 Million | -- |
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more